BMS-986525 for Relapsed Small Cell Lung Cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug called BMS-986525, alone or with other treatments, for people with small cell lung cancer that has come back or not responded to treatment. It aims to find out if the drug is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have small cell lung cancer that has come back or not responded to treatment.
- You have had at least one round of chemotherapy that included a platinum drug (like cisplatin or carboplatin).
- If standard first treatment in your country includes chemo with an anti-PD-(L)1 drug (like pembrolizumab), you must have already tried it, not be eligible for it, or not have access to it.
- Any cancer spread to the brain must have been treated and stable, not untreated.
- You cannot have an active or suspected autoimmune disease.
- You must not have had an organ or tissue transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, NMS-03305293, in adults with small cell lung cancer that has come back after earlier treatments. The goal is to see if it can help shrink or slow the cancer.
This trial is testing a new drug (BMS-986517) for people with advanced solid tumors, including certain lung, head and neck, and breast cancers. The goal is to see if the drug is safe and effective.
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
This study tests a new drug (GSK5764227) for people whose extensive-stage small cell lung cancer has gotten worse after platinum chemotherapy combined with immunotherapy. The goal is to see if this targeted treatment can help shrink tumors and control the cancer.
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
This trial tests a new drug called MHB088C for people with small cell lung cancer that has come back or gotten worse after standard treatments. It compares this drug to other options your doctor might choose. The goal is to see if MHB088C works better.
Hear when a new Relapsed/Refractory Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.